- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Melding nanotechnology and medical research, researchers from Sandia National Laboratories, the University of New Mexico, and the UNM Cancer Research and Treatment Center have produced an effective strategy that uses nanoparticles to treat tumors with a mélange of anticancer agents. This strategy relies on using silica nanoparticles honeycombed with cavities that can store large amounts and varieties of drugs loaded inside a lipid-based nanoparticle known as a liposome.
"The enormous capacity of the nanoporous core, with its high surface area, combined with the improved targeting of an encapsulating lipid bilayer, permits a single 'protocell' loaded with a drug cocktail to kill a drug-resistant cancer cell," says team leader Jeff Brinker, who is the co-principal investigator of the University of New Mexico Cancer Nanotechnology Platform Partnership. "That's a millionfold increase in efficiency over comparable methods employing liposomes alone — without nanoparticles — as drug carriers." Dr. Brinker and his team published the results of their work in the journal Nature Materials.
The nanoparticles and the surrounding cell-like membranes formed from liposomes create what the researchers call a protocell: the membrane seals in the deadly cargo and is modified with targeting molecules that bind specifically to receptors overexpressed on the cancer cell's surface. The nanoparticles provide stability to the supported membrane and release the therapeutic cargo within the cell.
A current Food and Drug Administration-approved nanoparticle delivery strategy is to use liposomes themselves to contain and deliver the cargo. In a head-to-head comparison of targeted liposomes and protocells with identical membrane and peptide compositions, Dr. Brinker and colleagues report that the greater cargo capacity, stability, and targeting efficacy of protocells leads to a drug formulation that is much more effective at killing human liver cancer cells.
Another advantage to protocells over liposomes alone is that it is far easier to load drugs into the porous nanoparticles than it is with liposomes. Loading drugs into liposomes requires complex strategies that boost the cost of making those formulations. In contrast, loading the porous nanoparticles can be done by simply soaking the nanoparticles in a drug solution. The liposome then serves as a shield that restricts toxic chemotherapy drugs from leaking from the nanoparticle until the protocell binds to the cancer cell. This means that only low levels of anticancer agents, at most, escape into the blood stream or attack other cells.
About The National Cancer Institute (NCI)
The NCI Alliance for Nanotechnology in Cancer is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat, and prevent cancer. Through its programs and initiatives, the Alliance is committed to building a community of researchers dedicated to using nanotechnology to advance the fight against cancer.
As part of the Center for Strategic Scientific Initiatives, the Alliance for Nanotechnology in Cancer works in concert with other NCI advanced technology initiatives to provide the scientific foundation and team science that is required to transform cancer research and care.
For more information, please click here
National Cancer Institute
Center for Strategic Scientific Initiatives
ATTN: NCI Office of Cancer Nanotechnology Research (OCNR)
Building 31, Room 10A52
31 Center Drive, MSC 2580
Bethesda, MD 20892-2580
Telephone: (301) 451-8983
Copyright © The National Cancer Institute (NCI)If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
X-rays and electrons join forces to map catalytic reactions in real-time: New technique combines electron microscopy and synchrotron X-rays to track chemical reactions under real operating conditions June 29th, 2015